RECODE THERAPEUTICS

Startup

RECODE THERAPEUTICS

Description

ReCode Therapeutics develops a selective organ targeting (SORT) lipid nanoparticle (LNP) platform designed for enabling precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics.

RECODE THERAPEUTICS

Address

1455 ADAMS DRIVE MENLO PARK, CALIFORNIA 94025 UNITED STATES
United States

Contact

partnering@recodetx.com

Description

ReCode Therapeutics develops a selective organ targeting (SORT) lipid nanoparticle (LNP) platform designed for enabling precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics.

Matchmaking

Connect with RECODE THERAPEUTICS

This entity is yours?

Update information

Position on the value chain

With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.

Bio-resources and biobanking
  • Cells, tissues and humanized xeno-organs
  • Biosamples
  • Viral, phage or bacterial specimen
Identification of biotherapies
  • Target identification
  • Target validation
  • Screening
Drug design
  • Drug assessment
  • Drug engineering
  • In vitro preclinical studies
Clinical validation
  • Clinical trials
  • In vivo preclinical validation
  • Pre-industrial scale production
Production
  • Upstream processes
  • Downstream processes
  • Quality control
Market access
  • CE mark / market authorisation
  • Payment / Reimbursement
  • Care pathways

TRL